A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Xenon Pharmaceuticals Inc.
- Study ID
- NCT06775379
- Phase
- PHASE3
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 74 Years
- Healthy Volunteers
- Not accepted
Interventions
- Azetukalner — DRUGAzetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks
- Placebo — DRUGPlacebo taken orally once a day with food (with the evening meal when possible) for 6 weeks
Study Details
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Key Dates
- Start date
- Dec 20, 2024
- Status verified
- Jan 2025
- Primary completion
- Aug 31, 2026
- Completion
- Oct 31, 2026
Study Design
- Enrollment
- 450 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: AzetukalnerAzetukalner 20 mg
- Placebo Comparator: PlaceboPlacebo
Primary Outcome Measure
Change from baseline in the Hamilton Depression Rating Scale, 17-item (HAMD-17) score at Week 6 [ Time Frame: Baseline to Week 6 ]
Central Contacts
- Xenon Medical Affairs1-604-484-3300
Locations (46)
Find similar trials in Phoenix, AZ
By condition
By specialty
Related Studies
- DBS for DepressionRecruiting · Baylor College of Medicine · Dallas, Texas
- Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar DisorderEARLY_PHASE1 · Recruiting · Massachusetts General Hospital · Boston, Massachusetts
- A Phase I/II Study of PDC-1421 for Treating Depression in Cancer PatientsPHASE1/PHASE2 · Not Yet Recruiting · BioLite, Inc. · Los Angeles, California
- Closed-Loop Deep Brain Stimulation for Major DepressionRecruiting · Andrew Krystal · San Francisco, California